Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Acerta Pharma BV
Mayo Clinic
AbbVie
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
AbbVie
AbbVie
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center